Monocytes Do Not Transdifferentiate into Proper Osteoblasts
Figure 1
Treatments to obtain PCMOs and MOMPs influence proliferation and expression of monocytes. (a) Human mononuclear cells (, ) were cultivated without specific treatment (Mo), treated for 6 days to obtain MOMPs (M) or PCMOs (P). Viability was measured by Alamar blue assay on day 6. P shows a significantly higher viability than Mo (***). (b) Relative expression levels of CD34 measured by RT-PCR normalized to GAPDH and subsequently to expression of CD34 in nonadherent bone marrow cells (naBMCs) as internal control (, ). Mo and M show a significantly higher expression of CD34 on day 6 than Mo on day 1 (**; ***). After osteogenic differentiation, CD34 levels in Mo decreased significantly in comparison to Mo on day 6 (°°). (c) Relative expression levels of collagen type 1 measured by RT-PCR normalized to GAPDH and subsequently to expression of collagen type 1 in primary osteoblasts (O) as internal control (, ). Mo, M and P show expression of low levels of collagen type 1 on all days (***). Monocytes (Mo) day 1: freshly isolated monocytes; Mo, MOMP (M), and PCMO (P) day 6: cells after treatment; Mo, M, P day 20: cells after differentiation with vitamin D containing medium.
